Assessing Technological Change in Cardiothoracic Surgery

Seminars in Thoracic and Cardiovascular Surgery

Volumn 21, Issue 1, 2009, Pages 28-34

  Iribarne, Alexander ^a,b   Russo, Mark J ^b   Moskowitz, Alan J ^a   Ascheim, Deborah D ^a   Brown, Lawrence D ^c   Gelijns, Annetine C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^c Mailman School of Public Health   (United States)

Author keywords

clinical trials; cost effectiveness; health policy; technology

Indexed keywords

ARTICLE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY BYPASS SURGERY; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH SERVICE; HUMAN; MEDICAL DECISION MAKING; MEDICARE; POLITICS; QUALITY CONTROL; THORAX SURGERY;

CARDIOVASCULAR SURGICAL PROCEDURES; DIFFUSION OF INNOVATION; EQUIPMENT DESIGN; EVIDENCE-BASED MEDICINE; GOVERNMENT REGULATION; HEALTH CARE COSTS; HEALTH EXPENDITURES; HEALTH PLANNING; HEALTH POLICY; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PUBLIC POLICY; TECHNOLOGY, MEDICAL; UNITED STATES;

EID: 67650747534     PISSN: 10430679     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2009.05.001     Document Type: Article

References (22)

1. Centers for Medicare and Medicaid Services. National Health Expenditures Data (2009), Centers for Medicare and Medicaid Services, Baltimore, MD. http://www.cms.hhs.gov/NationalHealthExpendData/ Available at: http://www.cms.hhs.gov/NationalHealthExpendData/
2. Andrews R.M., and Hungler B.P. The National Hospital Bill: The Most Expensive Conditions by Payer, 2006 (2008), Agency for Healthcare Research and Quality, Rockville, MD. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb59.pdf Available at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb59.pdf
3. Cutler D.M., and McClellan M. Is technological change in medicine worth it?. Health Aff 20 (2001) 11-29
4. The American Recovery and Reinvestment Act of 2009, in H.R. 1 (2009), The Library of Congress, Washington, DC. http://thomas.loc.gov/cgi-bin/query/z?c111:H.R.1.enr
5. Rose E.A., Gelijns A.C., Moskowitz A.J., et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 345 (2001) 1435-1443
6. Aaronson K.D., Patel H., Pagani F.D., et al. Patient selection for left ventricular assist device therapy. Ann Thorac Surg 75 suppl (2003) S29-S35
7. Lietz K., Long J.W., Kfoury A.G., et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: Implications for patient selection. Circulation 116 (2007) 497-505
8. Hlatky M., Lee K.L., Harrell Jr. F.E., et al. Tying clinical research to patient care by use of an observational database. Stat Med 3 (1984) 375-384
9. Nienaber C.A., Zannetti S., Barbieri B., et al. Investigation of stent grafts in patients with type B aortic dissection: Design of the INSTEAD trial-A prospective, multicenter, European randomized trial. Am Heart J 149 (2005) 592-599
10. Freemantle N., Calvert M., Wood J., et al. Composite outcomes in randomized trials. greater precision but with greater uncertainty?. J Am Med Assoc 289 (2003) 2554-2559
11. Hauptman P.J. Measurement of end points in heart failure trials: Jousting at windmills?. Mount Sinai J Med 71 (2004) 298-304
12. Serruys P.W., Morice M.C., Kappetein A.P., et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 360 (2009) 961-972
13. Tunis S.R., Stryer D.B., Clancy C.M., et al. Practical clinical trials: Increasing the value of clinical research for decision making in clinical and health policy. J Am Med Assoc 290 (2003) 1624-1632
14. Heitjan F., Moskowitz A.J., Whang W., et al. Problems with interval estimates of the incremental cost-effectiveness ratio. Med Decis Mak 19 (1999) 9-15
15. Garber A., and Phelps C.E. Economic foundations of cost-effective analysis. J Health Econ 16 (1997) 1-31
16. Finkelstein E., and Corso P. Cost-of-illness analyses for policy making: A cautionary tale for use and misuse. Pharmacoecon J Outcomes Res 3 (2003) 367-369
17. Inadomi J.M. Decision analysis and economic modeling: A primer. Eur J Gastroenterol Hepatol 6 (2004) 535-542
18. Oz M.C., Gelijns A.C., Miller L., et al. Left ventricular assist devices as permanent heart failure therapy: The price of progress. Ann Surg 238 (2003) 577-583
19. Blue C. Blue Shield Association Technology Evaluation Center: Special report: Cost-effectiveness of left-ventricular assist devices as destination therapy for end-stage heart failure. Chicago TEC Assessment Program 19 2 (2004) 1-35
20. Miller L.W., Nelson K.E., Bostic R.R., et al. Hospital costs for left ventricular assist devices for destination therapy: Lower costs for implantation in the post-REMATCH era. J Heart Lung Transplant 25 (2006) 778-784
21. Rector T., and Cohn J.N. Assessment of patient outcome with the Minnesota living with heart failure questionnaire: Reliability and validity during a randomized, double-blind, controlled trial of pimodbendan. Am Heart J 124 (1992) 1017-1025
22. Steinbrook R. Health care and the American Recovery and Reinvestment Act. N Engl J Med 360 (2009) 1057-1069